ラジオ波焼灼装置の世界市場-2025～2033年

世界のラジオ波焼灼装置市場は、2024年に56億3,000万米ドルに達し、2033年には135億4,000万米ドルに達すると予測され、予測期間2025～2033年のCAGRは10.7%で成長すると予測されています。

ラジオ波焼灼療法（RFA）は、高周波交流電流から熱を発生させ、それを用いて体内の特定の組織を除去または切除する低侵襲の医療処置です。この方法は、インターベンショナルラジオロジーや心臓病学など、さまざまな医療専門分野で広く用いられており、特に腫瘍や不整脈、慢性疼痛の治療に有用です。この方法は、目的の場所に極細の針またはカテーテルを挿入し、高周波を照射して局所的に加熱します。この熱によって異常組織が破壊され、その機能が低下または消失します。

RFAにはさまざまな用途があります。腫瘍学では、肝臓、肺、腎臓などの臓器の悪性腫瘍を破壊するために使用されます。心臓病学では、不整脈の原因となる心臓の誤った電気回路に対処するためにRFAが使用されます。また疼痛管理では、関節炎や腰痛などの慢性疼痛疾患の原因となる神経信号を破壊するために使用されます。RFAはその多用途性により、現代医療において不可欠な機器となっており、患者に最小限の侵襲で優れたヘルスケア代替手段を提供しています。

市場力学：

促進要因と抑制要因

ラジオ波焼灼装置に対する需要の増加

ラジオ波焼灼装置に対する需要の増加は、世界のラジオ波焼灼装置市場の成長において重要な要因となることが予想されます。オンボディドラッグデリバリーデバイスの需要は、慢性疾患の有病率の上昇、技術の進歩、低侵襲外科手術への嗜好の高まり、最近の発売や承認によって増加しています。

がん、心血管疾患、慢性疼痛のような慢性疾患が一般的になるにつれ、ヘルスケアプロバイダーは患者の苦痛や回復時間を軽減する効率的な治療法を探しています。例えば、米国心臓病学会（American College of Cardiology Foundation）によると、収縮期血圧の高値は年齢標準化したCVDの障害調整生存年（DALYs）に最も寄与しており、全世界の人口10万人当たり2,564.9人でした。

RFAは、隣接する健康な組織を保ちながら、異常な組織を正確に標的にできるため、魅力的なソリューションです。この特徴は特に腫瘍学において有用であり、RFAは固形腫瘍の治療に使用され、標準的な手術の候補となり得ない患者にとって実行可能な選択肢となります。市場はまた、さまざまな医療現場におけるこれらの機器の有効性、安全性、使いやすさを向上させる技術の進歩によっても牽引されています。ヘルスケアの情勢が変化する中、RFA技術の進歩は、世界的に一般的になりつつある慢性疾患や悪性腫瘍を含む幅広い疾患の治療において、これらの機器をより利用しやすく効果的なものにしています。RFA技術における最も重要な進歩の一つは、マルチニードル電極装置の導入です。これらの方法によって、より正確な組織ターゲティングが可能になり、医師はより広い範囲をより高い精度で治療できるようになると同時に、近くの健康な組織へのダメージを減らすことができるようになりました。この精度は腫瘍学において極めて重要であり、健康な組織を温存しながら腫瘍細胞を適切に切除できるかどうかが、患者の転帰に大きな影響を与えます。

さらに、RFA機器にリアルタイムモニター機能が搭載されたことで、臨床医は手術中に即座にフィードバックを得ることができます。この機能により、エネルギー供給プロセスの制御が向上し、治療中適切な温度が維持され、安全性と有効性の両方が改善されます。最近、ラジオ波焼灼装置の発売と承認が行われました。例えば、2024年10月、Boston Scientificは、発作性心房細動（AF）治療用のナビゲーション対応FARAWAVE NAVアブレーションカテーテルがFDAの承認を取得したと発表しました。また、FARAPULSEパルスフィールドアブレーション（PFA）システムと併用し、心臓アブレーション手技の視覚化を提供する新しいFARAVIEWソフトウェアのFDA 510（k）クリアランスも取得しました。これは、心臓アブレーション手技のために視覚化を提供するために、FARAPULSEパルスフィールドアブレーション（PFA）システムと併用されます。これらの技術は、Boston Scientificの既存の心臓マッピング技術と、同社の最新製品であるOPAL HDxマッピングシステムのみと互換性があります。

ラジオ波焼灼装置に関連する副作用と合併症

ラジオ波焼灼装置に伴う副作用や合併症などの要因は、世界のラジオ波焼灼装置市場の妨げになると予想されます。RFAは一般的に安全で侵襲の少ない治療法とされていますが、潜在的な危険性がないわけではないです。RFAを受ける患者は、注射部位付近の不快感、浮腫、過敏症などさまざまな副作用を持つ可能性があります。これらの症状は、日焼けに似た灼熱感やしびれとして現れることがあり、術後数日から数週間続くこともあります。このような不快感は、患者の不満を招き、将来的にこの治療を受けることに消極的になる可能性があり、市場全体の受容性と成長に影響を与えます。さらに、まれではありますが、RFA手術中あるいは手術後に、より重大な問題が生じることもあります。注入部位の感染、神経や血管の損傷、出血はすべて合併症の可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
  • ラジオ波焼灼装置の需要増加
  • 抑制要因
  • ラジオ波焼灼装置に関連する副作用と合併症
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析
• 償還分析
• 特許分析
• SWOT分析
• DMIの見解

第6章 コンポーネントタイプ別

• 使い捨て器具
• 設備投資
• 再利用可能な機器

第7章 用途別

• 外科腫瘍学
• 心臓病学と心拍リズム管理
• 美容
• 婦人科
• 疼痛管理

第8章 エンドユーザー別

• 病院
• 外来手術センター
• その他

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州地域
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第10章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第11章 企業プロファイル

• Boston Scientific Corporation
  • 会社概要
  • 製品ポートフォリオと概要
  • 財務概要
  • 主な発展
• Medtronic
• Stryker
• Abbott
• Smith+Nephew
• Johnson & Johnson Services, Inc.
• AngioDynamic
• Hologic, Inc.
• Arthrex, Inc.
• STARmed America

第12章 付録

The global radiofrequency ablation devices market reached US$ 5.63 billion in 2024 and is expected to reach US$ 13.54 billion by 2033, growing at a CAGR of 10.7% during the forecast period 2025-2033.

Radiofrequency ablation (RFA) is a minimally invasive medical procedure that generates heat from high-frequency alternating current and then uses it to eliminate or ablate certain tissues in the body. This procedure is widely used in a variety of medical specialties, including interventional radiology and cardiology, and is especially helpful in treating tumors, cardiac arrhythmias, and chronic pain. The method involves introducing a tiny needle or catheter into the desired location and applying radiofrequency radiation to induce localized heating. This heat causes the destruction of aberrant tissue, diminishing or eliminating its function.

RFA has a wide variety of applications. In oncology, it is used to destroy malignancies in organs like the liver, lungs, and kidneys. In cardiology, RFA is used to address faulty electrical circuits in the heart that cause arrhythmia. It is also used in pain management to disrupt nerve signals that cause chronic pain diseases including arthritis and lower back pain. RFA's versatility makes it an essential instrument in modern medicine, providing patients with superior healthcare alternatives that are minimally intrusive.

Market Dynamics: Drivers & Restraints

Increasing demand for radiofrequency ablation devices

The increasing demand for radiofrequency ablation devices is expected to be a significant factor in the growth of the global radiofrequency ablation devices market. The demand for on-body drug delivery devices is increasing owing to the rising prevalence of chronic diseases, technological advancements, growing preference for minimally invasive surgical procedures, and recent launches and approvals.

As chronic disorders like cancer, cardiovascular disease, and chronic pain become more common, healthcare providers are looking for efficient treatment alternatives that will reduce patient misery and recovery time. For instance, according to the American College of Cardiology Foundation, High systolic blood pressure contributed the most to age-standardized CVD disability-adjusted life years (DALYs), with 2,564.9 per 100,000 people worldwide.

RFA is an enticing solution because it enables precision targeting of aberrant tissues while maintaining adjacent healthy structures. This feature is especially useful in oncology, where RFA is used to treat solid tumors, giving it a viable option for patients who may not be candidates for standard surgery. The market is also driven by technological advancements that improve the efficacy, safety, and usability of these devices in a variety of medical settings. As the healthcare landscape changes, advances in RFA technology make these devices more accessible and effective for treating a wide range of ailments, including chronic diseases and malignancies, which are becoming more common worldwide. One of the most significant advances in RFA technology has been the introduction of multi-needle electrode devices. These methods enable more precise tissue targeting, allowing doctors to treat larger areas with higher accuracy while reducing damage to healthy tissues nearby. This accuracy is critical in oncology, where the ability to properly ablate tumor cells while conserving healthy structures has a substantial impact on patient outcomes.

Furthermore, the inclusion of real-time monitoring capabilities in RFA devices gives clinicians immediate feedback during operations. This feature provides greater control over the energy delivery process, ensuring that the proper temperature is maintained throughout the treatment, improving both safety and effectiveness. There are recent launches and approvals of radiofrequency ablation devices. For instance, in October 2024, Boston Scientific Corporation announced that the navigation-enabled FARAWAVE NAV Ablation Catheter for the treatment of paroxysmal atrial fibrillation (AF) has received FDA approval, as well as FDA 510(k) clearance for the new FARAVIEW Software, which will be used in conjunction with the FARAPULSE Pulsed Field Ablation (PFA) System to provide visualization for cardiac ablation procedures. These technologies are only compatible with Boston Scientific's existing cardiac mapping technology and the company's newest product, the OPAL HDx Mapping System.

Side effects and complications associated with radiofrequency ablation devices

Factors such as side effects and complications associated with radiofrequency ablation devices are expected to hamper the global radiofrequency ablation devices market. RFA is generally regarded as a safe and minimally intrusive therapy, however, it is not without potential hazards. Patients undergoing RFA may have a variety of side effects, including discomfort, edema, and hypersensitivity near the injection site. These symptoms might emerge as burning sensations or numbness, similar to sunburn, and may last for days or even weeks after the surgery. Such discomfort may cause patient discontent and reluctance to pursue this treatment in the future, affecting overall market acceptance and growth. Furthermore, more significant problems, albeit uncommon, can arise during or following the RFA operation. Infections at the injection site, nerve and blood vessel injury, and bleeding are all possible complications.

Segment Analysis

The global radiofrequency ablation devices market is segmented based on component type, application, end-user, and region.

Capital equipment segment is expected to dominate the global radiofrequency ablation devices market share

The capital equipment segment is anticipated to dominate the global radiofrequency ablation devices market owing to its increasing prevalence of chronic diseases, growing need for effective treatment options, technological advancements, and recent launches and approvals. This expansion relies heavily on capital equipment, which includes expensive goods such as radiofrequency generators and sophisticated ablation devices. These technologies improve both therapy efficacy and patient outcomes, making them indispensable in modern medical procedures. Furthermore, the capital equipment segment benefits from the continuing trend of technological innovation in healthcare. As hospitals and clinics invest in modern RFA systems, they become better prepared to manage complex cases requiring precision and dependability.

Technological advancements in RFA devices have resulted in increased precision and control during operations. Modern RFA systems use modern electrosurgical generators to deliver heat energy more precisely, allowing for targeted tissue destruction while protecting surrounding healthy tissue. These advances not only improve treatment outcomes but also cut recovery times, making RFA a more compelling alternative for patients. There are recent launches and approvals which are manufactured using advanced technology.

For instance, in October 2024, Abbott announced that it has completed two major milestones to support the company's growing suite of pulsed-field ablation (PFA) solutions in electrophysiology, early enrollment in the VOLT-AF IDE Study supporting the Volt PFA System, and the launch of the FOCALFLEX trial to assess the company's TactiFlex Duo Ablation Catheter, Sensor Enabled (SE), which will be used in the treatment of patients with paroxysmal atrial fibrillation. These two trials offer major benefits for the future of two Abbott PFA catheters, which are being developed as critical tools for clinicians treating patients with irregular heart rhythms like as atrial fibrillation (AFib).

Geographical Analysis

North America is expected to hold a significant position in the global radiofrequency ablation devices market share

North America will likely account for a significant share of the global radiofrequency ablation devices market, owing to its advanced healthcare infrastructure, increasing investments, a high prevalence of chronic diseases, technological advancements, and recent launches and approvals. This upward trend is primarily attributable to the increasing number of people suffering from chronic ailments such as cancer, arthritis, and cardiovascular disease.

For instance, according to the National Institute of Health, approximately 82.6 million people in the United States suffer from one or more forms of cardiovascular disease (CVD). Coronary heart disease (CHD), stroke, hypertension, and congestive heart failure are among the most common forms of cardiovascular disease. CHD affects an estimated 16.3 million Americans aged 20 and older, accounting for a 7% prevalence. The prevalence for men is 8.3 percent, while for women it is 6.1 percent. About 7 million Americans aged 20 and up have experienced a stroke. Each year, around 610,000 people have their first stroke, with another 185,000 experiencing a recurrence. Approximately 87 percent of all strokes are ischemic, with 10% caused by intracerebral hemorrhage and 3% by subarachnoid hemorrhage. Cardiovascular disease, diabetes, and autoimmune disorders are becoming more prevalent in the population. This frightening trend emphasizes the critical need for improved medical technologies capable of providing appropriate therapies for individuals suffering from chronic diseases.

The development of multi-needle electrodes and enhanced visualization techniques is one of the important technological advances that is driving the market. These advancements give more precision during surgeries, allowing medical professionals to target specific locations more effectively while limiting injury to neighboring tissues. Real-time imaging integration improves the visibility of anatomical features, which is critical for successful therapies. As a result, patients experience better outcomes and shorter recovery times, making RFA a better choice for both physicians and patients.

The market expansion is being driven by increasing expenditures on healthcare and a determined push to adopt modern medical technology, which is critical for tackling the growing prevalence of chronic diseases such as cancer and cardiovascular ailments.

The increased recognition of the benefits of radiofrequency ablation techniques is a major driver of this investment boom. As healthcare providers strive to improve patient outcomes while reducing costs, RFA technology investments have become a top priority. Hospitals and clinics are rapidly spending money to acquire cutting-edge RFA devices with improved precision and safety features. For instance, in June 2024, Kardium, the developer of a pulsed field ablation and mapping system for atrial fibrillation (AFib), announced that it has raised $104 million in the latest fundraising round to assist the firm prepare for commercialization. The funds will be used to finish Kardium's Pulsar clinical study, which is required to secure regulatory approval for their Globe mapping and ablation device. In addition, the company intends to increase its production team and capacity, as well as establish clinical support and commercial teams.

Asia Pacific is growing at the fastest pace in the global radiofrequency ablation devices market

The Asia Pacific region is emerging as the fastest-growing market for radiofrequency ablation devices, owing to a combination of demographic trends, increased healthcare investment, technological advancements, recent launches, and a rising number of chronic diseases. This increase is largely due to the increased prevalence of disorders like as cardiovascular disease (CVDs) and cancer, which require effective treatment alternatives such as RFA.

For instance, according to the National Institute of Health, Coronary heart disease prevalence rates in India have been calculated throughout the last several decades, ranging from 1.6% to 7.4% in rural populations and 1% to 13.2% in metropolitan areas. This disturbing development highlights the critical need for modern medical therapies, such as RFA, to successfully manage these chronic illnesses. The rising prevalence of chronic diseases in Asia Pacific is exacerbated by demographic changes, notably an aging population.

Competitive Landscape

The major global players in the global radiofrequency ablation devices market include Boston Scientific Corporation, Medtronic, Stryke, Abbott, Smith+Nephew, Johnson & Johnson Services, Inc., AngioDynamic, Hologic, Inc., Arthrex, Inc., STARmed America among others.

Emerging Players

Ananya Health, Sedivention, and Field Medical among others

Key Developments

• In December 2023, Ajax Health announced the establishment of Cortex, a new company focused on developing comprehensive ablation technology for treating atrial fibrillation (AFib), with an initial funding of $90 million. This investment round was led by prominent firms KKR and Hellman & Friedman, along with contributions from other investors, including AI Life Sciences. The funding will support Cortex's mission to create advanced diagnostic and pulsed-field ablation (PFA) catheters, which are essential for improving treatment outcomes for patients suffering from AFib.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global radiofrequency ablation devices market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Component Type
• 3.2. Snippet by Application
• 3.3. Snippet by End-User
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
  • 4.1.2. Increasing Demand for Radiofrequency Ablation Devices
  • 4.1.3. Restraints
  • 4.1.4. Side Effects and Complications Associated with Radiofrequency Ablation Devices
  • 4.1.5. Opportunity
  • 4.1.6. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Reimbursement Analysis
• 5.6. Patent Analysis
• 5.7. SWOT Analysis
• 5.8. DMI Opinion

6. By Component Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component Type
  • 6.1.2. Market Attractiveness Index, By Component Type
• 6.2. Disposable equipment*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Capital equipment
• 6.4. Reusable equipment

7. By Application

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 7.1.2. Market Attractiveness Index, By Application
• 7.2. Surgical oncology*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Cardiology & cardiac rhythm management
• 7.4. Cosmetology
• 7.5. Gynecology
• 7.6. Pain management

8. By End User

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 8.1.2. Market Attractiveness Index, By End User
• 8.2. Hospitals*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Ambulatory Surgical Centers
• 8.4. Others

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component Type
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.6.1. U.S.
    • 9.2.6.2. Canada
    • 9.2.6.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component Type
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.6.1. Germany
    • 9.3.6.2. U.K.
    • 9.3.6.3. France
    • 9.3.6.4. Spain
    • 9.3.6.5. Italy
    • 9.3.6.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component Type
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.6.1. Brazil
    • 9.4.6.2. Argentina
    • 9.4.6.3. Rest of South America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component Type
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.6.1. China
    • 9.5.6.2. India
    • 9.5.6.3. Japan
    • 9.5.6.4. South Korea
    • 9.5.6.5. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component Type
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. Boston Scientific Corporation*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Financial Overview
  • 11.1.4. Key Developments
• 11.2. Medtronic
• 11.3. Stryker
• 11.4. Abbott
• 11.5. Smith+Nephew
• 11.6. Johnson & Johnson Services, Inc.
• 11.7. AngioDynamic
• 11.8. Hologic, Inc.
• 11.9. Arthrex, Inc.
• 11.10. STARmed America

LIST NOT EXHAUSTIVE

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us